Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · IEX Real-Time Price · USD
22.86
-0.23 (-1.00%)
Jul 12, 2024, 4:00 PM EDT - Market closed

Denali Therapeutics Revenue

Denali Therapeutics had revenue of $295.39M in the twelve months ending March 31, 2024, with 191.13% growth year-over-year. In the year 2023, Denali Therapeutics had annual revenue of $330.53M with 204.74% growth.

Revenue (ttm)
$295.39M
Revenue Growth
+191.13%
P/S Ratio
11.04
Revenue / Employee
$663,798
Employees
445
Market Cap
3.26B USD

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2023330.53M222.07M204.74%
Dec 31, 2022108.46M59.80M122.90%
Dec 31, 202148.66M-287.00M-85.50%
Dec 31, 2020335.66M308.98M1,158.19%
Dec 31, 201926.68M-102.48M-79.35%
Dec 31, 2018129.16M--
Dec 31, 20170--
Dec 31, 20160--
Dec 31, 20150--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Oscar Health 6.54B
Amedisys 2.25B
Corcept Therapeutics 523.53M
Inari Medical 520.66M
Amicus Therapeutics 423.49M
TG Therapeutics 289.33M
Twist Bioscience 277.49M
Arcellx 131.66M
Revenue Rankings